New Delhi, 20 March (H.S.):
Pharmaceutical firm Speciality Medicines Limited has launched its initial public offering (IPO) on Friday, with the issue opening for subscription at ₹29.14 crore. The public can place bids for the IPO till 24 March 2026, with shares proposed to be listed on the BSE SME platform on 30 March 2026.
Key IPO Dates and Mechanics
The issue is a 100% fresh‑equity offer of 23.50 lakh shares with a face value of ₹10 each. The price band has been set at ₹117 to ₹124 per share, translating to a lot size of 1,000 shares. Retail investors must apply for at least two lots (2,000 shares), which means a minimum investment of about ₹2.34–₹2.48 lakh at the upper band price.
Allotment is scheduled for 25 March 2026, with allotted shares to be credited to demat accounts and refund initiation on 27 March 2026. By early afternoon on the opening day, the IPO had already received about 46% subscription, indicating strong initial investor interest.
Issue Structure and Allocation
The IPO is divided into three investor categories:Qualified Institutional Buyers (QIBs): Up to 2% of the issue
Retail investors: Minimum 49% reserved
Non‑Institutional Investors (NIIs): Minimum 49% reservedThe issue will be listed on the BSE SME segment, and the company plans to use the proceeds primarily for R&D infrastructure, international product registrations, marketing and working‑capital expansion in its specialty pharma business.
Financial Performance Highlights
According to the company’s draft red herring prospectus (DRHP) filed with SEBI, Speciality Medicines has shown consistent improvement in profitability and scale.
Key figures include:
Net profit:
FY 2023–24: ₹2.93 crore
FY 2024–25: ₹8.61 crore
Nine months April–October 2025 (current year): ₹6.06 crore
Total revenue:FY 2023–24: ₹27.66 crore
FY 2024–25: ₹58.54 crore
Nine months April–October 2025: ₹36.93 crore
Debt and net worth:
Debt: ₹2.86 crore (FY 2023–24) → ₹5.05 crore (FY 2024–25) → ₹4.81 crore (April–October 2025)
Net worth: ₹15.06 crore (FY 2023–24) → ₹23.98 crore (FY 2024–25) → ₹30.04 crore (April–October 2025)EBITDA: ₹5.26 crore (FY 2023–24) → ₹9.09 crore (FY 2024–25) → ₹6.51 crore (April–October 2025)
The company’s improving earnings, revenue growth and rising net worth suggest a strengthening financial profile ahead of its market debut.
Lead Managers and Registrars
Uniston Capital Private Limited is the Book Running Lead Manager for the issue, while Skyline Financial Services Private Limited has been appointed as Registrar. Aequum Capital Private Limited is the market maker for the stock post‑listing.
---------------
Hindusthan Samachar / Jun Sarkar
